Braid ball embolic device features

Information

  • Patent Grant
  • 9095342
  • Patent Number
    9,095,342
  • Date Filed
    Tuesday, November 9, 2010
    14 years ago
  • Date Issued
    Tuesday, August 4, 2015
    9 years ago
Abstract
Embolic implants and methods of manufacture are disclosed. The implants may be used for occluding blood flow at endovascular sites. One use is in intracranial aneurysm emolization/occlusion and another in parent vessel occlusion (PVO) or sacrifice. Various features provide for improved use (e.g., regarding delivery, recapture, visualization and/or occlusion) and manufacturability.
Description
BACKGROUND

Commonly-assigned International Application No. PCT/US2009/041313, now published as WO 2009/132045, describes a new class of braid-based embolization devices and delivery system interfaces. The implants may be used for occluding blood flow at endovascular sites. One use is in intracranial aneurysm embolization or occlusion and another in parent vessel occlusion (PVO) or sacrifice. Improvements to those devices are disclosed herein.


SUMMARY

Braid-ball devices formed with folded-over and folded-flat distal end are among the architectures described in WO 2009/132045. These architectures are the ones best suited for treating brain aneurysms. Distal marker approaches are described that are especially suited for such devices. In addition, proximal end finishing approaches are described that are suitable for these and the rest of the devices described in the '045 publication. All of the features and technologies presented in PCT/US2009/041313 (now WO 2009/132045) are incorporated herein by reference.


Regarding the distal marker approaches, one improvement comprises a tether to/for the distal marker included in the implant. Specifically, with the marker affixed adjacent the distal end of the implant (as in the folded-flat embodiments in the incorporated application), the length of the tether/tie extends to the proximal hub of the implant. It has a length set so that when the implant is compressed, the marker is pulled into alignment with the implant and/or catheter.


When a suture is employed for the tether, it can tie around the interior of the distal fold with minimal interference. However, it may be advantageous to use a wire ribbon (e.g., Pt or Nitinol) for other reasons.


Namely, a tether ribbon (especially when pre-formed into a “V” shape) can be threaded through the gap/hole and around as few as one wire from the braid. So-disposed, there is no interference with the compression of the distal end of the implant. What is more, spring action in the ribbon tether (whether comprising two filaments or trimmed to one after crimping, gluing, welding or otherwise affixing at least one marker) can help position the marker against/across the top of the implant when deployed. Such a ribbon can also contribute to marker radiopacity, thereby allowing a smaller marker size.


Another option is to include fibers and/or other thrombus promoting material in connection with the tether. Whatever material option is selected and/or additional features are provided, the proximal end of the tether is advantageously captured between the layers of braid or between the braid and either one of optional inner or outer bands. It may be glued-in, affixed by welding or otherwise.


Yet another set of improvements concerns the manner in which the implant is finished. By “finished”, what is meant is the manner in which the proximal side of the implant is managed to define a hub and/or delivery system detachment interface.


In one advantageous approach, in which use of an inner band is desired for interface with detachment system components (such as those described in the referenced application), processing is done with an elongate hypotube set within the braid. The hypotube (e.g., about 2-5 cm long) serves as a means to hold and manipulate an implant preform construct. In addition, when the tube is trimmed off (or when the final or near-final implant is trimmed off relative to the tube being held) the remaining portion of the hypotube within the implant (now the “inner band”) defines the detachment interface lumen. Likewise—especially when a more radiopaque material such as Pt/Ir or CoCr is used for the tube, the same structure will improve and/or offer the requisite radiopacity at the proximal end of the implant.


In all, the approach (optionally characterized as a “sacrificial hypotube length” approach) is useful for gluing but may also be applied in a welding technique. In fact, it may be especially useful in the latter context by providing shielding from weld slag and deformation for the proximal aperture/port to be exposed by trimming the tube to define the inner band in the implant. Namely, after welding, a clean cut can be made (e.g., with a diamond saw, laser cutting, EDM, etc.—as above) and then any deburring (by mechanical action, etching, EP or otherwise) can be performed on the newly-exposed face as desired.


In conjunction with a sacrificial hypotube length approach for gluing, or the original gluing approach described in the referenced application, another advantageous option is offered by a different post-processing step. Namely, after an outer band is used at the proximal end of the implant to define an outer casting boundary for adhesive/glue (e.g., Loctite 4014), it then may be removed leaving the underlying glue casting in place. Outer band removal offers potential to reduce all of the height, diameter and appearance of the size of the proximal feature of the implant. Accordingly, it may assist in developing a system with 0.021″ catheter crossing profile.


To facilitate removal, the band may advantageously comprise NiTi alloy (that naturally forms a passivation layer) or it may be coated or otherwise plated. A Titanium Nitride coating may be desirable. Spray mold release (e.g., 3M) or dip-coating in mold release may alternatively be employed to assist in slipping-off the band after adhesive application and curing. Otherwise, the band can be cut off the glue casting.


Another approach for achieving minimal implant hub diameter—while maintaining necessary radiopacity—involves affixing a platinum band on top of an inner NiTi band (i.e., in a linear arrangement). The proximal/lower NiTi section can be easily welded to the NiTi braid in the ball (when so-constructed) and the Pt (including Pt/Ir and other alloys) provides an in-line radiopaque marker. The detachment system control and anchor wires are received through both bands. The bands may be attached (e.g., by welding, gluing or soldering) or merely associated with each other until detachment system wire removal. In either case, they may include interference fit, puzzle-piece or other groove or tongue-and-groove features to make or assist in making a connection between the bodies.


Another set of improvements concerns shaping the distal end of a “folded-flat” type implant. It may be provided with a flattened top. The flattened top derives from a flat formed in the round tooling over which the braid is shaped. The flat can be produced by milling about 0.010″ off the form. This depth cut allows sufficient “table” for desired shaping and can be consistently applied across a range of implants sized from about 5 mm to 12 mm in diameter with little effect on the perceived shape. The resulting crease in the implant wire shaped by such a form offers an immediate advantage to implant deployment. With the flat placed so close to the distal end of the device, shape recovery of the bend/crease around the flattened top drives early opening of the implant when unsheathed (as compared to a situation where a crease formed around the flat is set further away—or none is provided).


Yet another set of implant improvements described herein augments the density of the ball. Stated otherwise, provision is made for an additional layer of braid material to further decrease the braid matrix porosity, and possibly do so without any increase in device crossing profile/delivery (micro)catheter compatibility.


These improvements involve a third layer of braid that is added to the two layers preferably already present in the folded-flat base implant architecture. In one variation, a third layer of braid is captured between the two layers and captured within the hub region, but trimmed proximal to the distal folded-over/flat section. In another variation, an inner layer is set within the envelope of the aforementioned two layers. It is advantageously attached to a distal end of the inner marker band (above/distal) to any outer marker band provided. As such, the braid's attachment will not increase the hub profile. To avoid any profile increase at the distal end of the implant, the inner layer will typically be trimmed so its compressed length is located proximal to the folded-over braid at the distal end of the implant when compressed. In its unconstrained form, the inner layer may simply define a cup. Alternatively, it may define a secondary ball shape. Such a ball shape may be substantially spherical or ovoid. One advantageous configuration further includes unterminated distal ends to the braid. The ends of the braid defining the inner ball may be secured in a band or welded together. So-configured they can offer another radiopaque marker feature within the ball. However, it may be preferred that the braid ends of the inner layer (in cup, ball form; or otherwise) are unterminated. As such, they may improve thrombus formation within the body of the implant.


Finally, delivery system improvements are described. The features described are “improvements”—as are the features noted above—in a contextual sense. For example, certain of the delivery system architectures may not be as space-efficient as others. Yet, such larger system(s) may be desirable for reason of reduced manufacturing complexity and/or cost.


The subject implant and delivery devices, kits in which they are included, methods of use and manufacture are all included within the scope of the present description. A number of aspects of such manufacture are discussed above. More detailed discussion is presented in connection with the figures below.





BRIEF DESCRIPTION OF THE FIGURES

The figures provided herein are not necessarily drawn to scale, with some components and features exaggerated for clarity. Variations from the embodiments pictured are contemplated. Accordingly, depiction of aspects and elements of embodiments in the figures are not intended to limit the scope of the description.


In the figures,



FIGS. 1A and 1B show an implant with a marker tether as expanded and being compressed, respectively;



FIGS. 2A and 2B show the distal end and a side view of another tethered-marker embodiment, respectively;



FIG. 3 is a detail view of a marker/tether subassembly;



FIG. 4 diagrammatically illustrates the assembly in FIG. 3 set within an implant;



FIG. 5 shows an implant preform prepared for proximal end finishing;



FIG. 6 shows the proximal end welded;



FIG. 7 shows an implant preform prepared for proximal end finishing according to another approach;



FIG. 8 shows the proximal end cut and welded;



FIGS. 9A and 9B show implants employing alternative proximal end finishing approaches, with a detail view in FIG. 9B of a low-profile embodiment;



FIGS. 10A and 10B show additional proximal end radiopaque features as may be employed with various end-finishing approaches;



FIG. 11 shows in implant formed with a distal flattened top;



FIG. 12 shows implant forms for imparting an implant shape as shown in FIG. 11 across a number of different implants of a given size range;



FIGS. 13A and 13B, respectively, illustrate the operation of an implant shaped according to FIG. 11/12 as compared to one that is not;



FIGS. 14-17 diagrammatically illustrate improved density implants as compared to the architecture presented in FIG. 4;



FIG. 18 shows an overview of an implant/detachment system interface as may be employed in connection with the present invention;



FIGS. 19A-19E and 20A-20E illustrate the stages of operation (handle-side and implant-side, respectively) of the system shown in FIG. 18;



FIG. 21 shows an optional improvement to the architecture of the same system;



FIGS. 22A and 22B show an alternative delivery system interface engaged and disengaged, respectively;



FIG. 23 is an end-on view of the delivery system interface as pictured in FIG. 22B.



FIGS. 24A and 24B illustrate alternative end-on views of the configuration of a pusher shaft in the same system;



FIGS. 25A and 25B show alternative delivery system interface options (engaged and disengaged, respectively) based on the pusher shaft configuration in FIG. 24B;



FIG. 26 shows an alternative implant-side interface with a delivery system as presented in FIGS. 25A and 25B;



FIG. 27 shows an implant-side interface like that presented in FIG. 26 with an alternative pusher-side architecture;



FIGS. 28A and 28B show an alternative engagement/disengagement interface for a system like that shown in FIGS. 22A and 22B;



FIGS. 29 and 30 show yet another engagement/disengagement architecture for each of a braid-type implant and embolic coil, respectively.





DETAILED DESCRIPTION

Various exemplary embodiments are described below. Reference is made to these examples in a non-limiting sense, as it should be noted that they are provided to illustrate more broadly applicable aspects of the devices, systems and methods. Various changes may be made to these embodiments and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the present invention. All such modifications are intended to be within the scope of the claims made herein.


To the extent any dimensions are stated in the summary or detailed description, such are intended to be merely examples and are not to limit the inventive subject matter unless explicitly recited in the claims.


Furthermore, the various features of the embodiments described herein are intended to be complement each other and are not intended to be purely alternatives unless stated so. In other words, features from one embodiment may be freely combined with features of another embodiment, as one of ordinary skill in the art will readily recognize, unless it is stated that those features are only to be used in the alternative. Applicants therefore intend this paragraph to provide written support for any present or future claim that recites features taken from different embodiments, should such not already be clear from the summary, detailed description, and claims.


Turning to the figures, FIGS. 1A and 1B show an implant 10. In FIG. 1A, only the hub (not visible) of implant 10 is received within a sheath or catheter 2. Roughly 40% of implant 10 is received within sheath 2 in FIG. 1B. A radiopaque marker 20 (e.g., a Pt band) is visible in both views. As in WO 2009/132045, and with further reference to FIG. 4, implant 10 includes a tie 22 positioned between braid layers 12 and 14 adjacent a distal fold 16 in the braid, which defines aperture 18 (also referred to herein as the hole or gap in the braid). Marker 20 is held by tie 22. Tie 22 may also assist in closing or limiting the size to which aperture 18 may open.


While tie 22 terminates adjacent marker 20 in WO 2009/132045, it extends to proximal hub 30 of implant 10 in the present description. The extension “tether” portions, or members 24 so-provided operate to ensure axial alignment of marker 20 when implant 10 is captured (especially when re-capturing) in a catheter/sheath.


The length of tether member(s) 24 is therefore set such that slack is present when the implant is expanded (as shown in FIG. 1A) and the slack is removed when the implant is fully compressed or tending thereto (as shown in FIG. 1B).


Whereas the tie and/or tether member(s) 24 shown in FIGS. 1A and 1B is typically made of suture material, it may be made of any other biocompatible material including stainless steel, titanium, Nitinol (possibly wire that is martinistic at body temperature-commonly referred to as “muscle wire”), and the like. When suture material is employed it can tie around the interior of distal fold 16 with minimal interference and be knotted at point 26 (see FIG. 1A) to easily secure the position of marker 20. The same approach may be accomplished with fine wire (e.g., 0.001 inch round wire.


It may instead be advantageous to use a wire ribbon (e.g., Pt or Nitinol) for other reasons. A construction as detailed in the next figures was made using a superelastic NiTi ribbon with dimensions set at about 0.001 inches by about 0.003 inches.


A tether ribbon 22 heatset into a tight loop or “V” shape was threaded through gap 20 and around as few as one wire from the braid at a distal end of implant 10 as shown in FIG. 4. So-disposed, tether ribbon 22 does not substantially interfere with compression of the distal end of the implant. What is more, spring action in the tether ribbon (whether comprising two filaments or trimmed to just one filament (as indicated by the broken line) after crimping, gluing, welding or otherwise affixing marker 20 as shown in FIG. 3) can help position marker 20 against (or across) the top of implant 10 when deployed, as shown in FIGS. 2A and 2B. As for affixing the marker, it is notable that the paired ribbon sections, stacked upon each other, provide a good interface upon which to crimp marker 20 without drastically altering the marker's shape.


Also, the length of the tether may optionally be set in a general “question-mark” shape to match (or more closely match) the curvature of the implant when unconstrained (e.g., as the tether appears in FIG. 4). Pre-shaping the tether to “match” (or approximately match) one or more implant sizes can help ensure predictable and similar performance of implants across a range of different implant sizes and compressions.


As stated above, another improvement to the subject implants concerns the manner of proximal end finishing. FIG. 5 shows an implant preform 60 prepared for proximal end finishing. Here, implant preform 60 such as prepared in WO 2009/132045 is prepared, leaving an additional overhang section 50 extending past a proximal marker band 32. In many respects, the setup resembles that shown in FIG. 13A of the '045 publication with the implant preform 60 including an inner NiTi tube 34 and the assembly set upon a mandrel 52. To maintain the position of the components as shown, glue (e.g., Loctite 4014) is applied. Even so, and referring also to FIG. 6, the hub region 30 can be welded effectively with a weld bead 54 incorporating the overhanging braid 50, inner tube 34 and at least tack-welding an outer Pt band 32. It is noteworthy that achieving such a near-optimal welding result through (or into) the glue stabilized braid was a surprising result. In other words, it was neither predictable nor expected by those of skill in the art of welding (laser or otherwise). In any case, the length of the braid overhang incorporated into weld 54 may vary depending on a number of factors including implant diameter, wire diameter, braid density, etc. As shown, the overhang is about 0.005 to about 0.010 inches in length.


Another proximal end finishing approach is described in connection with FIG. 7. Specifically, preform 62 is not trimmed and stabilized for welding as shown in FIG. 5. Rather, preform 62 is prepared upon an elongate hypotube 54. The hypotube body provides a means to hold the construct and stabilize its elongate “tail” section 56 of braid layer 12 and/or layer 14 (e.g., by a wrap 58) thereon.


With a narrow window defined (e.g., with about 0.010 to about 0.025 inches of—preferably—exposed braid) laser energy is applied as indicated by the larger area. The energy is sufficient to weld the braid to the hypotube. The welding process does not, however, weld the hypotube to the optional underlying mandrel 52.


After such welding, the majority of the length of hypotube 54 is “sacrificed”. It is trimmed-off to define the inner band 34 of the implant as shown in FIG. 8. This inner band may provide some or all of the radiopacity required in the hub region 30. However an outer band (especially if it comprises Pt) can be tack welded to the braid as indicated by the arrow Z in FIG. 7.


Irrespective of whether an outer marker band is included, FIG. 8 illustrates an advantage of the finishing approach, namely, the avoidance of weld bead flow artifacts associated with surface tension at the end of a body (as seen in FIG. 6). Rather, the weld 64 is neatly faced and the inner lumen of the remaining band 34 de-burred and/or reamed. Both actual and apparent hub size can be minimized accordingly.



FIGS. 9A and 9B illustrate another advantageous proximal end finishing approach for minimizing proximal hub size. FIG. 9A shows an implant with an outer marker band 32 as it will generally appear as affixed by glue or welding. In instances where such a band is affixed by glue, once a glue cast is formed therein the band can be removed. An implant 10′ will then include a proximal hub 30′ that is reduced in diameter (by as much as about 0.004 inches depending on band thickness) and is also less noticeable by offering less contrast. Outside the body (e.g., in packaging) a physician will see a glaze or sheen of adhesive/glue 70 as a cast 72 in which the braid is embedded instead of a high contrast marker 32.


While seemingly unimportant to function, this visual aspect can indeed be relevant. The impression of physicians regarding the bulk of the proximal feature can affect whether the physician adopts the product. Conventional implants have been designed with the proximal hub completely inset within the inner volume of the implant. This is done to make the implant's appearance more attractive to physicians. However, the implant suffers in performance as a result (e.g., the implant is more difficult to recapture; the requirements on the implant's wire size and strength are heightened to force the implant to recover the inset shape, leading to an undesirable increase in implant dimension; and other performance deficiencies). In the present aspect of the invention, the perceived hub size is reduced, which increases the visual appeal without compromising performance.



FIGS. 10A and 10B illustrate additional embodiments that eliminate the outer band while providing relatively increased radiopacity. Specifically, minimal implant hub size can be achieved by relocating a radiopaque band feature to an in-line arrangement with the inner band 34. A simple Pt band 74 can be set atop the inner band 34 as shown in FIG. 10A. These members may be joined using conventional techniques (i.e., gluing, soldering, welding, etc.) or be held in relation to one another on a temporary basis by utilizing delivery system interface members as shown in FIG. 18, etc. to the embodiment of FIG. 10B interlocks members 34 and 74 through the use of lock 76 and key 78 features.


Another implant feature is illustrated in connection with FIGS. 11 and 12. The implant optionally includes a flattened top 80 adjacent distal aperture 18. The flattened top is generated by providing a table surface 82 in the molding element 88 used to define the bulk shape of the implant. Molding elements, or “forms,” in different sizes 88, 88′ and 88″ are shown in FIG. 12. They are milled down from a spherical form to define flat 82 surrounded by edge 84. The edge produces a crease 86 in the braid wire. Note that flat 80 and crease 86 are shown in alternate views in FIGS. 2A and 2B.


During implant preform heatsetting, it has been found that the flat section improves the quality of the distal fold 16 in the implant, helping to maximize uniformity and minimize the bend radius in the wires. As such, device trackability through tortuous anatomy within a catheter is also improved. The crease at the edge of the flattened area set in the implant also helps with delivery performance upon deployment. Specifically, as illustrated in FIG. 13A, the crease 86 represents multiple bends in the wires forming the implant braid matrix. Upon exit from the microcatheter, the bends recover and cause the implant distal end to open more than an implant without such a crease as shown in FIG. 13B (see also, the implant in FIG. 1B). As a more open body, the implant is softer, with more relaxed braid angle should it contact any fragile tissue—such as the dome of an aneurysm.


Other architectural changes or augmentations that may be applied to implants are shown in FIGS. 14-17. Each approach offers the potential for diagrammatically improved density relative to the parent architecture illustrated in FIG. 4.


Specifically, implant 90 includes an intermediate braid layer 92 set between outer layer 12 and inner layer 14. Layer 92 is captured in hub 30 as are the other layers at a proximal attachment 94. The distal extent 96 can be set at a number of positions. Advantageously, it extends to around the half-way point or equator of the device. This way, the layer will contribute to implant density (or—stated otherwise—reduce porosity) even for wide-neck aneurysms.


As shown in FIG. 14, the distal extent 96 of the braid is adjacent to the folded-over section 16 of the implant. Here, the density is highest so the inner layer wires will tend to stay best trapped between layers 12 and 14. Yet, since the ends 96 do not interfere with the fold 16 (which can be the highest profile aspect of the implant) little or no increase in crossing profile need result.


In production, the inner layer 92 of the implant can be produced simply by cutting a preform (like preform 62) in half at the distal fold. This produces a set of two inner layer sections that can be used in two different devices from a single formation procedure. However produced, because the inner layer may rely on the other layers for structural definition, it may be made of finer wire and/or with lower braid count than the other layers. For instance, the inner layer may comprise 72-end 0.0008 inch wire braid, whereas the outer layers comprise 96-end 0.0008 inch wire braid. However, the reverse may be true, in which the inner layer is more robust. In any case, it may be advantageous to mismatch the number of wire ends included in the braid (such as in the example directly above) to help avoid wire match-up, thereby minimizing porosity.


Implant 100 shown in FIG. 15 illustrates another advantageous approach to improving flow disruption effect, without increasing device crossing profile. As in device 90, an intermediate braid layer 90 is employed. However its proximal end is not secured within the hub, thereby easing space constraints in that region.


Instead, braid matrix integrity is maintained by coating the braid layer with a polymer (e.g., TICOPHILIC coating by Lubrizol, Inc.) or other coatings or processing. Hydrogel coating also offers an appealing option, such as a hydrogel-based polymer network capable of entrapping therapeutic agents as described in U.S. Pat. No. 6,905,700 to Won et al. Likewise, while the implant elements advantageously comprise Nitinol braid (typically superelastic NiTi), the braid used for any of the layers may instead comprise polymer—especially high strength biodegradable polymer such as MX-2 (MAX-Prene), synthetic absorbable monofilament (90/10 Glycolide/L-Lactide) and/or G-2 (Glycoprene), synthetic absorbable monofilament (Glycolide (PGA), ε-Caprolactone (PCL), Trimethylene Carbonate (TMC) Copolymer) that is heat set into shape (e.g., at 110 degrees centigrade for an hour) and/or coated with the same to stabilize the braid matrix as described.


Implant 110 shown in FIG. 16 offers another yet another approach for improved embolizing (or flow disrupting) effect with little or no effect on crossing profile. Such effect is accomplished by affixing an innermost/third braid layer 112 to inner band 34 at its proximal end 114. It may be welded, glued, soldered or otherwise affixed thereto. The distal end of the braid 116 may be trimmed and formed as shown or otherwise. For example, the cup so-formed may closely follow the inner periphery of the device up to or past its equator.


As with variations in the previous figures, the third layer incorporated in the implant simply deploys and recaptures in unison with the rest of the implant. Unique, however, to the architecture of FIG. 16 is that the proximal end 114 of the braid is stably secured, but secured such that it does not require space in the hub (e.g., within the outer marker band 32) without dimensional stackup.


A related implant configuration is shown in FIG. 17. Here, in implant 120, the same proximal end 114 attachment approach is employed. Yet, instead of forming (e.g., by heatsetting) the inner layer of braid into a cup shape, an inner ball 118 is formed. The proximal side of the ball improves overall proximal-side implant density, and also defines separated flow stagnation zones A and B within the implant to further assist in thrombus formation within the implant.


Inner ball body 118 may be shape set over a form. Alternatively, and more advantageously, the shape can be formed without either an external or internal form by bunching the braid up and tying it onto a mandrel for heatsetting. Such a “free-forming” approach is functionally advantageous because it maximizes braid angle (hence, density) in the final body. Yet, any resulting inconsistency in shape is manageable given that the only outer body of the implant defined by braid layers 12 and 14 is in contact with an aneurysm.


Irrespective of how it is formed (and the particular braid configuration selection) the inner ball 118 within the architecture will be configured so that it will not interfere with the distal end of the implant body/shell and/or marker and tether when the device is compressed for delivery or recapture.


More generally, FIG. 18 provides an overview of implant-side of a treatment system 200. The system includes an implant 10 (90, 100, 110, 120) and a pusher/catheter shaft 210 ultimately attached to a handle 220 (e.g., as shown in FIGS. 19A-19-E). Any of these may be constructed according to the teachings herein and/or incorporated by reference.


One handle construction includes a single plunger. The plunger pulls a collar that progressively engages and pulls sockets connected to the wires; first each control wire 212 is pulled (one at a time), then the anchor wire 214. Such action is illustrated in FIGS. 19A-19E and 20A-20E. FIGS. 19A and 20A show the device components as removed from packaging. FIG. 19B illustrates unlocking the handle plunger 222 with a 120 degree rotation relative to handle body 224. Such action has no effect on the detachment interface 216 shown in FIG. 20B. However, progressive pull of the plunger in FIGS. 19C-19E effect the release of the system as shown in FIGS. 20C-20E.



FIG. 21 shows an optional improvement to the architecture of system 200. Here, system 200′ has only one “true” control wire 212 is received within the hub or inner band 30/34 of the implant 10. Even so, the implant remains securely/stably attached to the catheter shaft by virtue of the control wire interaction with anchor ball 216 (e.g., as formed by laser or as otherwise configured).


Release of the implant is effected as if progressing from the steps in FIGS. 19C and 20C to 19E and 20E. However, a third (floating or actuated) “dummy” wire 218 is still loaded within the lumen of pusher shaft 210. Use of this wire maintains a close-packed arrangement of the wires inside shaft 210, which can be important in determining wire position within a tortuous setting. Yet, release angle may be increased and plunger pull force reduced because the wires within the implant have more space between them allowing for spatial accommodation.


Note that the length “L” by which wire 218 is inset within the pusher shaft may vary depending on purpose. It may have no inset (i.e., essentially abut the implant proximal end). It may be inset by about 1 mm so that any forward motion in a tortuous setting does not result in contact with the implant. Or it may be inset to a greater degree (e.g., between about 1 cm and 5 cm) to improve distal tip flexibility of delivery pusher shaft 210.



FIGS. 22A and 22B show an alternative delivery system interface in engaged and disengaged states, respectively. Here, system 230 comprises a catheter/pusher shaft 232 actuated with the assistance of a typical torque 234. Torquer 234 locks a position of a central wire 236 including an anchor ball for implant 10 delivery. A bumper or shoulder 240 may be affixed to the catheter (optionally a Pt band also serving as a marker) to abut a hub 30 of the implant for pushing.


Engagement is achieved between the implant and pusher shaft by virtue of extension 242 that is offset into an interfering relationship with an inner band 34 of the implant when the anchor ball 238 is in a retracted position as shown in FIG. 22A. When wire 236 (and its terminal ball feature 238) is advanced as shown in FIG. 22B, extension section 242 is free to move (e.g., to return to its original position by elastic action or upon catheter shaft withdrawal) and slide out of the implant.



FIG. 23 is an end-on view of the delivery system interface as pictured in FIG. 22B. As shown, no interference between the ball 238 and/or extension persists once wire 236 is advanced. FIG. 24A portrays a similar view without the wire in place. It shows extension 242 and catheter body 232. And while they are illustrated as formed in one manner (i.e., with a 90 degree cut-down), it is to be appreciated that the extension may instead be formed by an angular cut or otherwise. Indeed, FIG. 24B shows an approach in which the extension section is formed by pushing over the catheter wall on one side to meet the other and optionally heat setting, fusing or gluing the component parts 242 and 242′ together.



FIGS. 25A and 25B show an alternative delivery system interface 250 option (engaged and disengaged, respectively) based on the pusher shaft extension configuration in FIG. 24B. Due to the increased wall thickness offered by the double wall layer, the system can work much as that shown in FIGS. 22A and 22B, except without need for a distal interference feature (i.e., anchor ball/band). As such, withdrawal of wire 236 will relieve the interference and unlock the pusher shaft 232 (specifically, the associated extension) for withdrawal from the implant 10.



FIG. 26 shows an alternative implant-side interface with a delivery system as presented in FIGS. 25A and 25B. Here an implant socket 260 is provided. Socket 260 may be defined by a cup 262 attached to one or more implant braid layers (12/14), by welding or otherwise, and a reducer tube 264 threaded, pressed or otherwise affixed in the proximal end of the cup. Note that with such an arrangement that implant pushing can be accomplished without a shoulder or other proximal interface. Instead, both push and pull (for withdrawal) force application can occur within the socket chamber. While such a socket will typically be larger than the previous interfaces shown, it is easily retrofit or used as and alternative to the screw-type release approaches employed in many vessel sacrifice and closure devices as sold by AGA Medical, Inc. and others.


The delivery system configuration in FIG. 27 shows the same implant-side interface 260, with an alternative pusher-side engagement/disengagement (or latch) architecture 270. This architecture is a simplified version of that shown in FIG. 18 of WO 2009/132045. Specifically, a pusher shaft 272 (e.g., metal hypotube) is provided with a single window cutout 274. The window (configured as a square cutout, rounded, or a simple kerf) allowing a core member 276 (e.g., NiTi ribbon) to pass therethrough and provide interference against pusher shaft distal face 276 to prevent delivery system detachment until core member withdrawal.



FIGS. 28A and 28B show an alternative latch interface 280 for a system like that shown in FIGS. 22A and 22B. In this system, a bent back wire hook 282 serves the function of the ball in the former system. Such a system offers the advantage of very low cost production, as well as a secure anchoring feature. FIG. 29 shows a system 290 most closely related to that in FIG. 21, except that multiple control and/or dummy wires are replaced with a single ribbon 292.


Finally, FIG. 30 shows a detachment system 300. As in system 290 a ribbon 292 may be used in conjunction with a round anchor wire 214 with a ball-shaped anchor 216. An alternative approach that may be used in either system is to employ a ribbon as the “anchor wire” and form the interference feature at its end by tying a knot therein (as a substitute for a laser-formed ball). Such a knot can be shape set, glued or welded to stabilize its shape. It can be reliably be produced at low cost at a very small size, on a ribbon. A socket-type interface can be formed within the coil by fitting a collar feature 302 within its proximal end. The collar may be threaded-in (i.e., into the coils like a thread pitch). An alternative approach involves flowing solder between the coils and defining a lumen therein using a removable mandrel. The mandrel may be prepared in any manner to facilitate its removal, including those described for the removable hub in connection with the improvement described in connection with FIG. 9B.


In the various delivery system architectures, the catheter/pusher shaft comprise a simple extrusion (e.g., PTFE, FEP, PEEK, etc.) or may be constructed using conventional catheter construction techniques and include a liner, braid support and outer jacket (not shown). An exemplary construction is available through MicroLumen, Inc. as Braid Reinforced Polyimide. A distal section of the Polyimide may be ablated and replaced with fused Pebax to provide a softer or progressively-flexible end to the catheter. A loading sheath is typically provided over the pusher shaft. Advantageously, the loading sheath is splittable.


If not preloaded, after removal from sterile packaging (not shown), the implant is pulled into the loading sheath. The loading sheath is received within the hub of the catheter to be used for implant delivery and the implant is advanced into the catheter. Then, the implant may be advanced to and deployed at a treatment site. Or it may be retrieved in exchange for another size implant—else repositioned, if desired, prior to ultimate detachment as illustrated in the incorporated patent application subject matter.


In the present invention, the subject methods may include each of the physician activities associated with implant positioning and release. As such, methodology implicit to the positioning and deployment of an implant device forms part of the invention. Such methodology may include placing an implant within a brain aneurysm, or at parent vessel targeted for occlusion, or other applications. In some methods, the various acts of implant introduction to an aneurysm or parent vessel are considered.


More particularly, a number of methods according to the present invention involve the manner in which the delivery system operates in reaching a treatment site, for example. Other methods concern the manner in which the system is prepared for delivering an implant, for example attaching the braid ball to the delivery system. Any method herein may be carried out in any order of the recited events which is logically possible, as well as in the recited order of events, or slight modifications of those events or the event order.


It is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein. Reference to a singular item, includes the possibility that there is a plurality of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said,” and “the” include plural referents unless specifically stated otherwise. In other words, use of the articles allow for “at least one” of the subject item in the description above as well as the claims below. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.


Without the use of such exclusive terminology, the term “comprising” in the claims shall allow for the inclusion of any additional element irrespective of whether a given number of elements are enumerated in the claim, or the addition of a feature could be regarded as transforming the nature of an element set forth in the claims. Except as specifically defined herein, all technical and scientific terms used herein are to be given as broad a commonly understood meaning as possible while maintaining claim validity.


The breadth of the present invention is not to be limited to the examples provided and/or the subject specification, but rather only by the scope of the claim language. Use of the term “invention” herein is not intended to limit the scope of the claims in any manner. Rather it should be recognized that the “invention” includes the many variations explicitly or implicitly described herein, including those variations that would be obvious to one of ordinary skill in the art upon reading the present specification. Further, it is not intended that any section of this specification (e.g., the Summary, Detailed Description, Abstract, Field of the Invention, etc.) be accorded special significance in describing the invention relative to another or the claims. All references cited are incorporated by reference in their entirety. Although the foregoing invention has been described in detail for purposes of clarity of understanding, it is contemplated that certain modifications may be practiced within the scope of the appended claims.

Claims
  • 1. An implant comprising: a self-expandable body having proximal and distal ends and expanded and compressed configurations,a radiopaque marker positioned within an interior volume of the body and held adjacent the distal end by at least one filament coupled to the proximal and distal ends,wherein the at least one filament crosses the interior volume of the body extending from the marker and terminating at the proximal end, andwherein the at least one filament has a length about equal to a length of the body in the compressed configuration such that (i) the marker is misaligned with respect to a longitudinal axis of the body when the implant is unconstrained in the expanded configuration and (ii) the marker is aligned with the longitudinal axis of the body when the body is in the compressed configuration.
  • 2. The implant of claim 1, wherein the at least one filament comprises suture material, and a first end of the suture material is coupled to a proximal end of the marker and a second end of the suture material is coupled to the body proximal end.
  • 3. The implant of claim 1, wherein the at least one filament comprises metal weldable to the body for securement at the proximal end of the body.
  • 4. The implant of claim 3, wherein the filament is in the form of round wire.
  • 5. The implant of claim 3, wherein the filament is in the form of ribbon.
  • 6. The implant of claim 1, wherein the body comprises a braided layer.
  • 7. The implant of claim 1, wherein the radiopaque marker is coupled to the body.
  • 8. An implant comprising: a self-expandable body having longitudinal axis, proximal and distal ends, and expanded and compressed configurations;at least one filament, having a length about equal to a length of the body in the compressed configuration, extending within the body and coupled to the proximal and distal ends; anda radiopaque marker attached to the at least one filament such that the marker is (i) misaligned with respect to the longitudinal axis in the expanded configuration and (ii) aligned with the longitudinal axis in the compressed configuration.
  • 9. The implant of claim 8, wherein the body comprises a braided layer.
  • 10. The implant of claim 8, wherein the radiopaque marker is coupled to the body.
  • 11. The implant of claim 8, wherein the at least one filament is in the form of round wire.
  • 12. The implant of claim 8, wherein the at least one filament is in the form of ribbon.
  • 13. The implant of claim 8, wherein the at least one filament comprises suture material, and a first end of the suture material is coupled to a proximal end of the marker and a second end of the suture material is coupled to the body proximal end.
  • 14. The implant of claim 8, wherein the at least one filament comprises metal weldable to the body for securement at the proximal end of the body.
  • 15. The implant of claim 8, wherein in the expanded configuration, the at least one filament is slack such that the marker is misaligned with respect to a longitudinal axis of the body, and in the compressed configuration, the at least one filament is aligned with the longitudinal axis.
  • 16. The implant of claim 8, wherein in the collapsed configuration, the body comprises a collapsed axial length that is substantially equal to a length of the at least one filament such that the at least one filament is aligned with the longitudinal axis in the collapsed configuration.
  • 17. The implant of claim 8, wherein a first end of the at least one filament is attached to the proximal end and a second end of the at least one filament is attached to the distal end.
  • 18. The implant of claim 1, wherein the at least one filament is fixedly attached to the distal end of the implant in the compressed configuration.
  • 19. The implant of claim 1, wherein the at least one filament is coupled to at least one of the distal or proximal ends of the body.
  • 20. An implant comprising: a self-expanding body having a longitudinal axis, proximal and distal ends, and expanded and compressed configurations; anda radiopaque marker component, having a length about equal to a length of the body in the compressed configuration, extending within the body and having first and second ends being coupled to the respective proximal and distal ends, the marker component being (i) misaligned with respect to the longitudinal axis, and slack under the action of gravity, in the expanded configuration and (ii) aligned with the longitudinal axis in the compressed configuration.
  • 21. The implant of claim 20, wherein the marker component comprises at least one filament.
  • 22. The implant of claim 20, wherein an end of the marker component is fixedly attached to an end of the body.
CROSS-RELATED APPLICATION

This application claims priority to U.S. Provisional Application Ser. No. 61/259,585, filed Nov. 9, 2009, which is incorporated herein by reference in its entirety.

US Referenced Citations (401)
Number Name Date Kind
4425908 Simon Jan 1984 A
4619246 Molgaard-Nielsen et al. Oct 1986 A
4655771 Wallsten Apr 1987 A
4768507 Fischell et al. Sep 1988 A
4921484 Hillstead May 1990 A
4998539 Delsanti Mar 1991 A
5026377 Burton et al. Jun 1991 A
5061275 Wallsten et al. Oct 1991 A
5064435 Porter Nov 1991 A
5104404 Wolff Apr 1992 A
5122136 Guglielmi et al. Jun 1992 A
5222971 Willard et al. Jun 1993 A
5250071 Palermo Oct 1993 A
5334210 Gianturco Aug 1994 A
5378239 Termin et al. Jan 1995 A
5405379 Lane Apr 1995 A
5425984 Kennedy et al. Jun 1995 A
5484444 Braunschweiler et al. Jan 1996 A
5499981 Kordis Mar 1996 A
5527338 Purdy Jun 1996 A
5545208 Wolff et al. Aug 1996 A
5549635 Solar Aug 1996 A
5624461 Mariant Apr 1997 A
5634942 Chevillon et al. Jun 1997 A
5645558 Horton Jul 1997 A
5690671 McGurk et al. Nov 1997 A
5725552 Kotula et al. Mar 1998 A
5728906 Eguchi et al. Mar 1998 A
5733294 Forber et al. Mar 1998 A
5741333 Frid Apr 1998 A
5749891 Ken et al. May 1998 A
5749919 Blanc May 1998 A
5749920 Quiachon et al. May 1998 A
5766151 Valley et al. Jun 1998 A
5814062 Sepetka et al. Sep 1998 A
5830230 Berryman et al. Nov 1998 A
5846261 Kotula et al. Dec 1998 A
5879366 Shaw et al. Mar 1999 A
5911731 Pham et al. Jun 1999 A
5916235 Guglielmi Jun 1999 A
5925060 Forber Jul 1999 A
5928228 Kordis et al. Jul 1999 A
5928260 Chin et al. Jul 1999 A
5935148 Villar et al. Aug 1999 A
5935362 Petrick Aug 1999 A
5941249 Maynard Aug 1999 A
5944738 Amplatz et al. Aug 1999 A
5951599 McCrory Sep 1999 A
5957948 Mariant Sep 1999 A
5980554 Lenker et al. Nov 1999 A
6010517 Baccaro Jan 2000 A
6024756 Huebsch et al. Feb 2000 A
6033423 Ken et al. Mar 2000 A
6036720 Abrams et al. Mar 2000 A
6063070 Eder May 2000 A
6063104 Villar et al. May 2000 A
6086577 Ken et al. Jul 2000 A
6093199 Brown et al. Jul 2000 A
6096034 Kupiecki et al. Aug 2000 A
6096073 Webster et al. Aug 2000 A
6099526 Whayne et al. Aug 2000 A
6123715 Amplatz Sep 2000 A
6139564 Teoh Oct 2000 A
6152144 Lesh et al. Nov 2000 A
6168592 Kupiecki et al. Jan 2001 B1
6168615 Ken et al. Jan 2001 B1
6168618 Frantzen Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6183495 Lenker et al. Feb 2001 B1
6190402 Horton et al. Feb 2001 B1
6193708 Ken et al. Feb 2001 B1
6221086 Forber Apr 2001 B1
6261305 Marotta et al. Jul 2001 B1
6306141 Jervis Oct 2001 B1
6309367 Boock Oct 2001 B1
6322576 Wallace et al. Nov 2001 B1
6325820 Khosravi et al. Dec 2001 B1
6331184 Abrams Dec 2001 B1
6332576 Colley et al. Dec 2001 B1
6342068 Thompson Jan 2002 B1
6344041 Kupiecki et al. Feb 2002 B1
6344048 Chin et al. Feb 2002 B1
6346117 Greenhalgh Feb 2002 B1
6350270 Roue Feb 2002 B1
6361558 Hieshima et al. Mar 2002 B1
6368339 Amplatz Apr 2002 B1
6375668 Gifford et al. Apr 2002 B1
6383174 Eder May 2002 B1
6391037 Greenhalgh May 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6428558 Jones et al. Aug 2002 B1
6443972 Bosma et al. Sep 2002 B1
6447531 Amplatz Sep 2002 B1
6454780 Wallace Sep 2002 B1
6506204 Mazzocchi Jan 2003 B2
6511468 Cragg et al. Jan 2003 B1
6530934 Jacobsen et al. Mar 2003 B1
6547804 Porter et al. Apr 2003 B2
6551303 Van Tassel et al. Apr 2003 B1
6569179 Teoh et al. May 2003 B2
6579303 Amplatz Jun 2003 B2
6585748 Jeffree Jul 2003 B1
6585756 Strecker Jul 2003 B1
6589256 Forber Jul 2003 B2
6589265 Palmer et al. Jul 2003 B1
6592605 Lenker et al. Jul 2003 B2
6599308 Amplatz Jul 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6605111 Bose et al. Aug 2003 B2
6607551 Sullivan et al. Aug 2003 B1
6613074 Mitelberg et al. Sep 2003 B1
6626939 Burnside et al. Sep 2003 B1
6632241 Hancock et al. Oct 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6635069 Teoh et al. Oct 2003 B1
6652555 VanTassel et al. Nov 2003 B1
6652556 VanTassel et al. Nov 2003 B1
6666882 Bose et al. Dec 2003 B1
6666883 Seguin et al. Dec 2003 B1
6669717 Marotta et al. Dec 2003 B2
6669721 Bose et al. Dec 2003 B1
6676696 Marotta et al. Jan 2004 B1
6682505 Bates et al. Jan 2004 B2
6682546 Amplatz Jan 2004 B2
6689150 VanTassel et al. Feb 2004 B1
6689486 Ho et al. Feb 2004 B2
6695876 Marotta et al. Feb 2004 B1
6698877 Urlaub et al. Mar 2004 B2
6699274 Stinson Mar 2004 B2
6712835 Mazzocchi et al. Mar 2004 B2
6723112 Ho et al. Apr 2004 B2
6723116 Taheri Apr 2004 B2
6730108 Van Tassel et al. May 2004 B2
6746468 Sepetka et al. Jun 2004 B1
6746890 Gupta et al. Jun 2004 B2
6780196 Chin et al. Aug 2004 B2
6792979 Konya et al. Sep 2004 B2
6797083 Peterson Sep 2004 B2
6802851 Jones et al. Oct 2004 B2
RE38653 Igaki et al. Nov 2004 E
6811560 Jones et al. Nov 2004 B2
6855153 Saadat Feb 2005 B2
6855154 Abdel-Gawwad Feb 2005 B2
RE38711 Igaki et al. Mar 2005 E
6860893 Wallace et al. Mar 2005 B2
6936055 Ken et al. Aug 2005 B1
6949103 Mazzocchi et al. Sep 2005 B2
6949113 Van Tassel et al. Sep 2005 B2
6953472 Palmer et al. Oct 2005 B2
6979341 Scribner et al. Dec 2005 B2
6989019 Mazzocchi et al. Jan 2006 B2
6994092 van der Burg et al. Feb 2006 B2
6994717 Kónya et al. Feb 2006 B2
7011671 Welch Mar 2006 B2
7018401 Hyodoh et al. Mar 2006 B1
7029487 Greene, Jr. et al. Apr 2006 B2
7033375 Mazzocchi et al. Apr 2006 B2
7048752 Mazzocchi et al. May 2006 B2
7063679 Maguire et al. Jun 2006 B2
7070607 Murayama et al. Jul 2006 B2
7070609 West Jul 2006 B2
7083632 Avellanet et al. Aug 2006 B2
7128073 van der Burg et al. Oct 2006 B1
7128736 Abrams et al. Oct 2006 B1
7169177 Obara Jan 2007 B2
7195636 Avellanet et al. Mar 2007 B2
7211109 Thompson May 2007 B2
7229461 Chin et al. Jun 2007 B2
7232461 Ramer Jun 2007 B2
7261720 Stevens et al. Aug 2007 B2
7303571 Makower et al. Dec 2007 B2
7306622 Jones et al. Dec 2007 B2
7331980 Dubrul et al. Feb 2008 B2
7367985 Mazzocchi et al. May 2008 B2
7367986 Mazzocchi et al. May 2008 B2
7371250 Mazzocchi et al. May 2008 B2
7404820 Mazzocchi et al. Jul 2008 B2
7410482 Murphy et al. Aug 2008 B2
7410492 Mazzocchi et al. Aug 2008 B2
7413622 Peterson Aug 2008 B2
7419503 Pulnev et al. Sep 2008 B2
7442200 Mazzocchi et al. Oct 2008 B2
7485088 Murphy et al. Feb 2009 B2
7556635 Mazzocchi et al. Jul 2009 B2
7566338 Mazzocchi et al. Jul 2009 B2
7569066 Gerberding et al. Aug 2009 B2
7572273 Mazzocchi et al. Aug 2009 B2
7572288 Cox Aug 2009 B2
7597704 Frazier et al. Oct 2009 B2
7608088 Jones et al. Oct 2009 B2
7621928 Thramann et al. Nov 2009 B2
7670355 Mazzocchi et al. Mar 2010 B2
7670356 Mazzocchi et al. Mar 2010 B2
7678130 Mazzocchi et al. Mar 2010 B2
7682390 Seguin Mar 2010 B2
7691124 Balgobin Apr 2010 B2
7695488 Berenstein et al. Apr 2010 B2
7699056 Tran et al. Apr 2010 B2
7727189 VanTassel et al. Jun 2010 B2
7744583 Seifert et al. Jun 2010 B2
7744652 Morsi Jun 2010 B2
7763011 Ortiz et al. Jul 2010 B2
7828815 Mazzocchi et al. Nov 2010 B2
7828816 Mazzocchi et al. Nov 2010 B2
7906066 Wilson et al. Mar 2011 B2
7922732 Mazzocchi et al. Apr 2011 B2
7955343 Makower et al. Jun 2011 B2
7972359 Kreidler Jul 2011 B2
7993364 Morsi Aug 2011 B2
RE42758 Ken et al. Sep 2011 E
8062379 Morsi Nov 2011 B2
8075585 Lee et al. Dec 2011 B2
8142456 Rosqueta et al. Mar 2012 B2
8202280 Richter Jun 2012 B2
8221445 van Tassel et al. Jul 2012 B2
8261648 Marchand et al. Sep 2012 B1
8298257 Sepetka et al. Oct 2012 B2
8430012 Marchand et al. Apr 2013 B1
20010000797 Mazzocchi May 2001 A1
20010012949 Forber Aug 2001 A1
20010051822 Stack et al. Dec 2001 A1
20020013599 Limon et al. Jan 2002 A1
20020013618 Marotta et al. Jan 2002 A1
20020042628 Chin et al. Apr 2002 A1
20020062091 Jacobsen et al. May 2002 A1
20020165572 Saadat Nov 2002 A1
20020169473 Sepetka et al. Nov 2002 A1
20030004538 Secrest et al. Jan 2003 A1
20030028209 Teoh et al. Feb 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030171739 Murphy et al. Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030195553 Wallace et al. Oct 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030199919 Palmer et al. Oct 2003 A1
20040015224 Armstrong et al. Jan 2004 A1
20040034386 Fulton et al. Feb 2004 A1
20040044391 Porter Mar 2004 A1
20040098027 Teoh et al. May 2004 A1
20040098030 Makower et al. May 2004 A1
20040106945 Thramann et al. Jun 2004 A1
20040106977 Sullivan et al. Jun 2004 A1
20040111112 Hoffmann Jun 2004 A1
20040122467 VanTassel et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040143286 Johnson et al. Jul 2004 A1
20040162606 Thompson Aug 2004 A1
20040172056 Guterman et al. Sep 2004 A1
20040181253 Sepetka et al. Sep 2004 A1
20040186562 Cox Sep 2004 A1
20040193206 Gerberding et al. Sep 2004 A1
20040215332 Frid Oct 2004 A1
20040249408 Murphy et al. Dec 2004 A1
20040267346 Shelso Dec 2004 A1
20050010281 Yodfat et al. Jan 2005 A1
20050021077 Chin et al. Jan 2005 A1
20050033408 Jones et al. Feb 2005 A1
20050033409 Burke et al. Feb 2005 A1
20050060017 Fischell et al. Mar 2005 A1
20050096728 Ramer May 2005 A1
20050096732 Marotta et al. May 2005 A1
20050107823 Leone et al. May 2005 A1
20050131443 Abdel-Gawwad Jun 2005 A1
20050228434 Amplatz et al. Oct 2005 A1
20050267568 Berez et al. Dec 2005 A1
20050273135 Chanduszko et al. Dec 2005 A1
20060052816 Bates Mar 2006 A1
20060064151 Guterman et al. Mar 2006 A1
20060106421 Teoh May 2006 A1
20060116713 Sepetka et al. Jun 2006 A1
20060116714 Sepetka et al. Jun 2006 A1
20060155323 Porter et al. Jul 2006 A1
20060167494 Suddaby Jul 2006 A1
20060190070 Dieck et al. Aug 2006 A1
20060190076 Taheri Aug 2006 A1
20060206199 Churchwell et al. Sep 2006 A1
20060206200 Garcia et al. Sep 2006 A1
20060235464 Avellanet et al. Oct 2006 A1
20060235501 Igaki Oct 2006 A1
20060241690 Amplatz et al. Oct 2006 A1
20060247680 Amplatz et al. Nov 2006 A1
20060264905 Eskridge et al. Nov 2006 A1
20060264907 Eskridge et al. Nov 2006 A1
20060271149 Berez et al. Nov 2006 A1
20060271153 Garcia et al. Nov 2006 A1
20060276827 Mitelberg et al. Dec 2006 A1
20060292206 Kim et al. Dec 2006 A1
20060293744 Peckham et al. Dec 2006 A1
20070005125 Berenstein et al. Jan 2007 A1
20070016243 Ramaiah et al. Jan 2007 A1
20070021816 Rudin Jan 2007 A1
20070088387 Eskridge et al. Apr 2007 A1
20070093889 Wu et al. Apr 2007 A1
20070106311 Wallace et al. May 2007 A1
20070135826 Zaver et al. Jun 2007 A1
20070150045 Ferrera Jun 2007 A1
20070162104 Frid Jul 2007 A1
20070173928 Morsi Jul 2007 A1
20070191884 Eskridge et al. Aug 2007 A1
20070191924 Rudakov Aug 2007 A1
20070198075 Levy Aug 2007 A1
20070203567 Levy Aug 2007 A1
20070219619 Dieck et al. Sep 2007 A1
20070221230 Thompson et al. Sep 2007 A1
20070225760 Moszner et al. Sep 2007 A1
20070225794 Thramann et al. Sep 2007 A1
20070233244 Lopez et al. Oct 2007 A1
20070239261 Bose et al. Oct 2007 A1
20070265656 Amplatz et al. Nov 2007 A1
20070270902 Slazas et al. Nov 2007 A1
20070288083 Hines Dec 2007 A1
20080009934 Schneider et al. Jan 2008 A1
20080021535 Leopold et al. Jan 2008 A1
20080039933 Yodfat et al. Feb 2008 A1
20080045996 Makower et al. Feb 2008 A1
20080045997 Balgobin et al. Feb 2008 A1
20080058856 Ramaiah et al. Mar 2008 A1
20080065145 Carpenter Mar 2008 A1
20080097495 Feller, III et al. Apr 2008 A1
20080109063 Hancock et al. May 2008 A1
20080114391 Dieck et al. May 2008 A1
20080114436 Dieck et al. May 2008 A1
20080114439 Ramaiah et al. May 2008 A1
20080119886 Greenhalgh et al. May 2008 A1
20080125806 Mazzocchi et al. May 2008 A1
20080140177 Hines Jun 2008 A1
20080154286 Abbott et al. Jun 2008 A1
20080195139 Donald et al. Aug 2008 A1
20080219533 Grigorescu Sep 2008 A1
20080221600 Dieck et al. Sep 2008 A1
20080249562 Cahill Oct 2008 A1
20080281350 Sepetka et al. Nov 2008 A1
20080319533 Lehe Dec 2008 A1
20090025820 Adams Jan 2009 A1
20090069806 De La Mora Levy et al. Mar 2009 A1
20090082803 Adams et al. Mar 2009 A1
20090099647 Glimsdale et al. Apr 2009 A1
20090112251 Qian et al. Apr 2009 A1
20090118811 Moloney May 2009 A1
20090143851 Paul, Jr. Jun 2009 A1
20090198315 Boudjemline Aug 2009 A1
20090210047 Amplatz et al. Aug 2009 A1
20090216307 Kaufmann et al. Aug 2009 A1
20090228029 Lee Sep 2009 A1
20090259202 Leeflang et al. Oct 2009 A1
20090264914 Riina et al. Oct 2009 A1
20090275974 Marchand et al. Nov 2009 A1
20090287291 Becking et al. Nov 2009 A1
20090287294 Rosqueta et al. Nov 2009 A1
20090287297 Cox Nov 2009 A1
20090318941 Sepetka et al. Dec 2009 A1
20100004726 Hancock et al. Jan 2010 A1
20100004761 Flanders et al. Jan 2010 A1
20100023105 Levy et al. Jan 2010 A1
20100030200 Strauss et al. Feb 2010 A1
20100042133 Ramzipoor et al. Feb 2010 A1
20100069948 Veznedaroglu et al. Mar 2010 A1
20100094335 Gerberding et al. Apr 2010 A1
20100131002 Connor et al. May 2010 A1
20100152767 Greenhalgh et al. Jun 2010 A1
20100268260 Riina et al. Oct 2010 A1
20100274276 Chow et al. Oct 2010 A1
20100312270 McGuckin, Jr. et al. Dec 2010 A1
20100331948 Turovskiy et al. Dec 2010 A1
20110022149 Cox et al. Jan 2011 A1
20110144669 Becking et al. Jun 2011 A1
20110152993 Marchand et al. Jun 2011 A1
20110184452 Huynh et al. Jul 2011 A1
20110184453 Levy et al. Jul 2011 A1
20110196415 Ujiie et al. Aug 2011 A1
20110202085 Loganathan et al. Aug 2011 A1
20110208227 Becking Aug 2011 A1
20110245862 Dieck et al. Oct 2011 A1
20110265943 Rosqueta et al. Nov 2011 A1
20110313447 Strauss et al. Dec 2011 A1
20120041470 Shrivastava et al. Feb 2012 A1
20120065720 Strauss et al. Mar 2012 A1
20120143237 Cam et al. Jun 2012 A1
20120143317 Cam et al. Jun 2012 A1
20120165803 Bencini et al. Jun 2012 A1
20120165919 Cox et al. Jun 2012 A1
20120197283 Marchand et al. Aug 2012 A1
20120245674 Molaei et al. Sep 2012 A1
20120245675 Molaei et al. Sep 2012 A1
20120283768 Cox et al. Nov 2012 A1
20120316598 Becking et al. Dec 2012 A1
20120330341 Becking et al. Dec 2012 A1
20120330347 Becking et al. Dec 2012 A1
20130066360 Becking et al. Mar 2013 A1
20130085522 Becking et al. Apr 2013 A1
20130092013 Thompson et al. Apr 2013 A1
20130123830 Becking et al. May 2013 A1
20130211495 Halden et al. Aug 2013 A1
20130233160 Marchand et al. Sep 2013 A1
20130239790 Thompson et al. Sep 2013 A1
20130245667 Marchand et al. Sep 2013 A1
20130268053 Molaei et al. Oct 2013 A1
20130274862 Cox et al. Oct 2013 A1
20130274863 Cox et al. Oct 2013 A1
20130274866 Cox et al. Oct 2013 A1
20130274868 Cox et al. Oct 2013 A1
Foreign Referenced Citations (60)
Number Date Country
101472537 Jul 2009 CN
102008028308 Apr 2009 DE
775470 May 1997 EP
855170 Jul 1998 EP
1621148 Feb 2006 EP
1637176 Mar 2006 EP
1752112 Feb 2007 EP
1942972 Jul 2008 EP
1872742 May 2009 EP
2279023 Feb 2011 EP
2363075 Sep 2011 EP
2496299 Sep 2012 EP
2675402 Dec 2013 EP
2556210 Apr 1988 FR
2890306 Mar 2007 FR
11-506686 Jun 1999 JP
2003520103 Jul 2003 JP
2003-524434 Aug 2003 JP
2004-049585 Feb 2004 JP
2005-522266 Jul 2005 JP
2006-506201 Feb 2006 JP
2008-541832 Nov 2008 JP
4673987 Apr 2011 JP
WO-8800813 Feb 1988 WO
WO-9601591 Jan 1996 WO
WO 9726939 Jul 1997 WO
WO-9903404 Jan 1999 WO
WO 9903404 Jan 1999 WO
WO-9905977 Feb 1999 WO
WO 9905977 Feb 1999 WO
WO-9908607 Feb 1999 WO
WO-9908743 Feb 1999 WO
WO-9962432 Dec 1999 WO
WO 9962432 Dec 1999 WO
WO 0193782 Dec 2001 WO
WO 0200139 Jan 2002 WO
WO 02071977 Sep 2002 WO
WO 2005117718 Dec 2005 WO
WO 2006026744 Mar 2006 WO
WO-2006034166 Mar 2006 WO
WO 2006052322 May 2006 WO
WO 2006091891 Aug 2006 WO
WO-2006119422 Nov 2006 WO
WO-2007047851 Apr 2007 WO
WO-2007076480 Jul 2007 WO
WO 2007121405 Oct 2007 WO
WO 2008022327 Feb 2008 WO
WO 2008151204 Dec 2008 WO
WO 2008157507 Dec 2008 WO
WO-2009076515 Jun 2009 WO
WO 2009132045 Oct 2009 WO
WO 2009134337 Nov 2009 WO
WO-2009135166 Nov 2009 WO
WO-2010028314 Mar 2010 WO
WO 2010030991 Mar 2010 WO
WO-2011057002 May 2011 WO
WO 2011057277 May 2011 WO
WO-2011130081 Oct 2011 WO
WO-2011153304 Dec 2011 WO
WO-2012112749 Aug 2012 WO
Non-Patent Literature Citations (20)
Entry
U.S. Appl. No. 60/948,683, filed Jul. 9, 2007.
U.S. Appl. No. 61/044,822, filed Apr. 14, 2008.
PCT/US, 2009/041313 Partial International Search Report, Sep. 30, 2009.
PCT/US, 2009/041313, International Search Report, Jan. 14, 2010.
CN, Serial No. 200980114155.5 Office Action, Mar. 29, 2012.
EP, Serial No. 11173658.3 EESR, May 8, 2012.
EP, Serial No. 11173659.1 EESR, May 8, 2012.
EP, Serial No. 11189200.6 EESR, May 8, 2012.
EP, Serial No. 12150960.8 ESR, Jun. 6, 2012.
EP, Serial No. 12150959.0 ESR, Jun. 12, 2012.
EP, Serial No. 11184201.9 EESR, Sep. 5, 2012.
U.S. Appl. No. 12/427,635—Final Office Action, Jan. 31, 2013.
Thorell, et al., “Y-configured Dual Intracranial Stent-assisted Coil Embolization for the Treatment of Wide-necked Basilar Tip Aneurysms”, Neurosurgery, May 2005, vol. 56, Issue 5, pp. 1035-1040.
Hill, et al., “Initial Results of the Amplatzer Vascular Plug in the Treatment of Congenital Heart Disease, Business Briefing,” US Cardiology 2004.
Ronnen, “Amplatzer Vascular Plug Case Study, Closure of Arteriovenous Fistula Between Deep Femoral Artery and Superficial Femoral Vein,” AGA Medical Corporation, May 2007.
U.S. Appl. No. 13/629,678, filed Sep. 28, 2012.
U.S. Appl. No. 13/669,652, filed Nov. 6, 2012.
U.S. Appl. No. 13/826,298, filed Mar. 14, 2013.
U.S. Appl. No. 13/795,556, filed Mar. 12, 2013.
U.S. Appl. No. 13/962,267, filed Aug. 8, 2013.
Related Publications (1)
Number Date Country
20110319926 A1 Dec 2011 US
Provisional Applications (1)
Number Date Country
61259585 Nov 2009 US